Abstract
There are numerous inborn errors of metabolism of the liver, and they are all rare to very rare. To get a clear picture of the indications for gene transfer in these conditions, it is essential to get a clear view on the current (lack of) insight in the pathophysiology of these disorders, the current treatment options and hence on the window of opportunity for new treatments as gene transfer. The aim of this review, is to illustrate the problems related to treatment of inborn errors of metabolism of the liver. General aspects defining the quest for treatments for very rare diseases are touched upon, but for the sake of clarity, this review is restricted to five illustrative examples: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia and propionic acidemia. These examples reflect the problems that are currently experienced and can be expected, when gene transfer trials for these disorders are undertaken.
Keywords: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia, propionic academia, phototherapy, bilirubin, cirrhosis, phenylalanine hydroxylase gene, Propionic acidemia
Current Pharmaceutical Design
Title: Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Volume: 17 Issue: 24
Author(s): David Cassiman
Affiliation:
Keywords: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia, propionic academia, phototherapy, bilirubin, cirrhosis, phenylalanine hydroxylase gene, Propionic acidemia
Abstract: There are numerous inborn errors of metabolism of the liver, and they are all rare to very rare. To get a clear picture of the indications for gene transfer in these conditions, it is essential to get a clear view on the current (lack of) insight in the pathophysiology of these disorders, the current treatment options and hence on the window of opportunity for new treatments as gene transfer. The aim of this review, is to illustrate the problems related to treatment of inborn errors of metabolism of the liver. General aspects defining the quest for treatments for very rare diseases are touched upon, but for the sake of clarity, this review is restricted to five illustrative examples: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia and propionic acidemia. These examples reflect the problems that are currently experienced and can be expected, when gene transfer trials for these disorders are undertaken.
Export Options
About this article
Cite this article as:
Cassiman David, Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective, Current Pharmaceutical Design 2011; 17 (24) . https://dx.doi.org/10.2174/138161211797247596
DOI https://dx.doi.org/10.2174/138161211797247596 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets Uric Acid and Oxidative Stress
Current Pharmaceutical Design Lipotoxicity Disrupts Erythrocyte Function: A Perspective
Cardiovascular & Hematological Disorders-Drug Targets Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Apelin in the Control of Body Fluid Homeostasis and Cardiovascular Functions
Current Pharmaceutical Design The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Cryoballoon Ablation for the Treatment of Atrial Fibrillation: A Meta-analysis
Current Cardiology Reviews The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Spontaneous Coronary Artery Dissection: Does Being Unemployed Matter? Insights from the GSCAD Registry
Current Cardiology Reviews Perioperative Management of Obese Parturients
Current Women`s Health Reviews Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Voltammetric Stripping Methods for Direct Determination of Disopyramide
Current Pharmaceutical Analysis Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine SynB3 Conjugated QBP1 Passes Blood-Brain Barrier Models and Inhibits PolyQ Protein Aggregation
Protein & Peptide Letters Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Caveolin-3: Its Importance in Muscle Function and Pathology
Current Genomics